473 filings
Page 5 of 24
8-K
i73b4i9ni ojzyo
25 Oct 21
ADMA Biologics Announces Closing of $57.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
4:30pm
424B5
v7fpec40m8 wolniqwe
21 Oct 21
Prospectus supplement for primary offering
4:36pm
8-K
2h9n 0k57nf
21 Oct 21
ADMA Biologics Announces Pricing of Public Offering for $50 Million of Common Stock
4:30pm
424B5
e59am9q98j
20 Oct 21
Prospectus supplement for primary offering
5:16pm
8-K
dkw278jntdgdom4hgs28
20 Oct 21
ADMA Biologics Announces Proposed Public Offering of Common Stock
4:26pm
8-K
q0k0 e27379l2ga
18 Oct 21
Departure of Directors or Certain Officers
5:28pm
8-K
anjr00iu dd7
1 Oct 21
Departure of Directors or Certain Officers
5:05pm
8-K
m975x
3 Sep 21
Entry into a Material Definitive Agreement
5:03pm
424B5
mvi4lw9
3 Sep 21
Prospectus supplement for primary offering
5:01pm
8-K
qxkqh5 869s1f
17 Aug 21
Termination of a Material Definitive Agreement
4:46pm
8-K
rl9 jlq2zlv0i
16 Aug 21
ADMA Biologics Receives FDA Approval for ADMA BioCenters Plasma Collection Facility in Maryville, TN
5:15pm
8-K
kvh7d7h27inpjcrbhhjl
12 Aug 21
ADMA Biologics Reports Record Second Quarter 2021 Financial Results and Highlights Recent Progress and Accomplishments
12:00am
8-K
yvd6wza1l341in5657
12 Aug 21
ADMA Expands Commercial IG Product Offering with Additional BIVIGAM and NABI-HB Vial Sizes
12:00am
EFFECT
8tdcg9t9
4 Aug 21
Notice of effectiveness
12:15am
CORRESP
onbzlcii 0cf
30 Jul 21
Correspondence with SEC
12:00am
8-K
h93dvp7wo4
27 Jul 21
Other Events
7:00am
8-K
g9s0dn3frvwel
20 Jul 21
ADMA Biologics Announces Successful Completion of FDA Pre-Approval Manufacturing Facility Inspection
4:31pm
8-K
w3qrw
14 Jun 21
Departure of Directors or Certain Officers
5:00pm